

LY2090314

Wnt/ β -Catenin pathway activator / GSK-3 inhibitor

Wnt/ β -catenin pathway activator. LY2090314 is a highly potent and selective inhibitor of glycogen synthase-3-kinase (GSK-3). It stabilized β -catenin levels and elevated expression of Axin2 leading to tumor growth delays in A375 melanoma xenografts. LY2090314 significantly reduced growth in multiple neuroblastoma cell lines. It inhibited growth and induced apoptosis in osimertinib-resistant lung cancer cells, specifically those with a mesenchymal phenotype.


Ordering Information

[Order Online »](#)

ENZ-CHM458-0025	25mg
-----------------	------

Manuals, SDS & CofA

[View Online »](#)



Handling & Storage

Use/Stability As indicated on product label or CoA when stored as recommended.

Long Term Storage -20°C

Shipping Ambient Temperature

Regulatory Status RUO - Research Use Only

Product Details

Alternative Name 3-[6-Fluoro-10-(piperidine-1-carbonyl)-1,10-diazatricyclo[6.4.1.0^{4,13}]trideca-2,4,6,8(13)-tetraene-3-yl]-4-imidazo[1,2-a]pyridine-3-ylpyrrole-2,5-dione

Appearance Orange solid.

CAS 603288-22-8

Couple Type Activator, Inhibitor

Formula C₂₈H₂₅FN₆O₃

Identity Determined by NMR.

MW 512.54

Purity ≥98% (HPLC)

Solubility Soluble in DMSO (>20 mg/ml).

Last modified: January 24, 2025



ENZO LIFE SCIENCES,
INC.
Phone: 800.942.0430
[info-
usa@enzolifesciences.com](mailto:info-usa@enzolifesciences.com)

European Sales Office
ENZO LIFE SCIENCES
(ELS) AG
Phone: +41 61 926 8989
[info-
eu@enzolifesciences.com](mailto:info-eu@enzolifesciences.com)

Belgium, The Netherlands
& Luxembourg
Phone: +32 3 466 0420
[info-
fr@enzolifesciences.com](mailto:info-fr@enzolifesciences.com)

France
Phone: +33 472 440 655
[info-
fr@enzolifesciences.com](mailto:info-fr@enzolifesciences.com)

Germany
Phone: +49 7621 5500 526
[info-
de@enzolifesciences.com](mailto:info-de@enzolifesciences.com)

UK & Ireland
Phone (UK customers):
0845 601 1488
Phone: +44 1392 825900
[info-
uk@enzolifesciences.com](mailto:info-uk@enzolifesciences.com)